Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Sai‐Hong Ignatius Ou
- ISSN / E-ISSN
- — / —
- DOI
- 10.2147/dddt.s19045 ↗
- Volume · Issue · Pages
- 5 · — · 471-471
- Publisher
- Dove Medical Press Ltd.
- Article URL
- https://doi.org/10.2147/dddt.s19045 ↗
- Article details
- Unverified
Publication date (each date has its type and source)
01 Nov 2011
OpenAlex publication date · source: OpenAlex
| Type | Date | Source |
|---|---|---|
| OpenAlex publication date | 01 Nov 2011 | OpenAlex |
Keywords (as given): crizotinib; anaplastic lymphoma kinase rearrangement; non-small cell lung cancer; ALK inhibitors; tyrosine kinase inhibitors; EGFR tyrosine kinase inhibitors; targeted therapy; drug development; adverse events; pneumonitis
HEC Status at Publication Not the journal's current status
HEC Status at PublicationNot conclusive
Historical status could not be conclusively determined.
- HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
Best available information, not a definitive status: HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
- Journal
- Drug Design, Development and Therapy
- Publication date used
- 01 Nov 2011 (OpenAlex publication date)
- Applicable HEC period
- None recorded for this date
- Category
- —
- Recognition status
- Unknown (NO_PERIOD_FOR_DATE)
- Source
- —
- Verification status
- Not available
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.